As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...

WASHINGTON, DC—Updated data from the SMART trial show that supra-annular self-expanding valves yield similar clinical outcomes as balloon-expandable valves at 2 years, but with less risk of ...

The study is published in the Journal of the American College of Cardiology, JACC, and shows that it is less dangerous than previously believed to receive a small bioprosthetic aortic valve in ...